Search PubMed⌕ Search

Biomedical subjects

A Murakami

Publications and source records attributed to A Murakami.

At least 217 records · Page 12Linked to original sources
PubMed1996

[Isolated rupture of the ventricular septum caused by nonpenetrating trauma--a case report of operation in acute stage].

We experienced a case of the isolated ventricular septal defect due to nonpenetrating chest trauma. The patient was 22-year-old male who hit his chest with a steering wheel on car accident. The echocardiogram examined on the next day revealed a ventricular septal defect. Four days after the injury, intracardiac repair was performed. On cardiopulmonary bypass the ventricular perforation (35 x 35 mm size) located in the muscular portion near the apex was closed with a PTFE and equestrian pericardial patch. Postoperative cardiopulmonary function could improve enough to wean from IABP and respiratory support. However, the patient died on the fifth postoperative day of severe hepatic failure due to profound shock persisted after the accident.

Accidents, Traffic↗
PubMed1996

[Surgical results of total replacement of aortic root].

Total aortic root replacement was performed on 19 cases since December 1979 to May 1995. They were devided in two groups. First 7 cases were operated by original Bentall procedure with inclusion technique (group A). Succeeding 12 cases were operated by Carrel patch method or Cabrol procedure without inclusion maneuver. There were 2 operative deaths in group A (28.6%) and was one death in group B (8.3%) respectively. The operation time and the extracorporeal circulation time were significantly shorter in group A than that in group B. Anastomotic leakage was noted in 2 cases of group A. One of them required reoperation and another one with coronary ostial leakage died of congestive heart failure. We concluded that non-inclusion method for aortic root replacement was superior to conventional inclusion technique and reimplantation of both coronary ostia with Carrel patch method was the best tactics especially for Marfan syndrome in terms of long term results.

Adult↗
PubMed1996

[An operative case of suture-granuloma which resulted from an intra-pulmonary treatment 10 years ago and manifested hemoptysis].

We experienced a 27-year-old male patient with recurrent hemoptysis manifested by granuloma which resulted from surgical repair that was performed for right pneumothorax using unabsorbable sutures (braided silk) before 10 years. The patient had been suffering from fever and cough for three months before hemoptysis. Chest X-ray and CT scan films showed a mass shadow in the lateral side of the right lung field. Furthermore, bronchoscopy revealed bleeding in B3 of the right lung. The patient underwent right upper lobectomy, which disclosed that hemoptysis was due to a granuloma (2.3 x 3.2 cm in size) formed around sutures. The granuloma was caused not only by foreign body reaction but also by transbronchial infection.

Adult↗
PubMed1996

[Coronary artery bypass grafting for acute myocardial infarction].

Five hundred and fourteen cases with acute myocardial infarction were admitted to our hospital during the past 5 years, since April 1990. Among 343 cases who had emergency coronary angiography, 53 cases had coronary artery bypass grafting surgery within 2 weeks after the onset of acute myocardial infarction. Mean number of bypass grafts was 2.9 +/- 0.9/patient, and operative mortality was 25% (13/53). Clinical condition immediately before the surgery and surgical mortality was, shock state in 20 cases (mortality 50%), IABP dependent state in 23 cases (mortality 13%), post-infarction angina in 8 cases (mortality 0%). Mortality in 8 cases whose infarct-related artery was left main trunk was as high as 63%. Eight of 9 cases whose cardiac indices were below 2.01/min/m2 immediately after the surgery died of pump failure. On the contrary, only 2 of 37 cases whose post-operative cardiac indices were above 2.01/min/m2 died of non-cardiac reason. To improve the surgical results, we concluded that powerful mechanical support such as ventricular assist system should be applied to post-operative pump failure cases whose cardiac indices were below this limit despite the aid of IABP.

Adolescent↗
PubMed1995

Cholesterol sulfate, a second messenger for the eta isoform of protein kinase C, inhibits promotional phase in mouse skin carcinogenesis.

Cholesterol sulfate is a second messenger for the eta isoform of protein kinase C mediating squamous differentiation. We found that cholesterol sulfate inhibited the promotional phase of skin carcinogenesis in female CD-1 mice, which was initiated by 100 micrograms 7,12-dimethylbenz[a]-anthracene and promoted by a single application of 10 micrograms 12-O-tetradecanoylphorbol-13-acetate, followed by repeated applications of 10 micrograms mezerein once a week for 19 weeks. Cholesterol sulfate, when applied topically at a dose of 400 micrograms (820 mumol) 10 min before treatment with the promoters, markedly suppressed tumor formation, resulting in decrease of 56% in the incidence of tumor-bearing mice, 81% in the number of tumors/mouse, and 60% in the size of tumors at 20 weeks of the promotion. This inhibition was not due to elimination of the initiated cells. Treatment with the parental cholesterol at a dose of 320 micrograms (820 mumol), which does not activate the eta isoform, did not inhibit tumor promotion. Repeated treatment with cholesterol sulfate induced scaling of skin at the site of application. Cholesterol sulfate, unlike most inhibitors of tumor promotion, did not inhibit induction of ornithine decarboxylase and hyperplasia in mouse epidermis caused by topical treatment with 12-O-tetradecanoylphorbol-13-acetate. These findings suggest that cholesterol sulfate inhibits tumor promotion by stimulating a differentiation pathway mediated by the eta isoform of protein kinase C.

9,10-Dimethyl-1,2-benzanthracene↗
PubMed1995

Screening for in vitro anti-tumor promoting activities of edible plants from Thailand.

A total of 112 species of edible plants (122 samples) from Thailand were randomly collected, and their methanol extracts were screened for in vitro anti-tumor promoting activity using the inhibition test of Epstein-Barr virus (EBV) activation in Raji cells induced by 12-O-hexadecanoylphorbol-13-acetate (HPA, 40 ng/ml). It was found that 60% of these extracts inhibited EBV activation by 30% or more at a concentration of 200 mg/ml. Significantly, the ratio is markedly higher than that (26%) previously observed in common edible plants in Japan. Thus, physiological potentiality of edible Thai plants has been implied in terms of cancer chemoprevention.

Anticarcinogenic Agents↗
PubMed1995

Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells.

Oligonucleotides complementary to the sequences containing the initiator codon, AUG, of the core region of positive-stranded hepatitis C virus (HCV) were tested for their effects on viral translation in a cell-free protein synthesis system and on viral replication in a human T-lymphotropic virus type I infected cell line, MT-2C, which was cloned by the limited dilution method from MT-2 cells and showed more efficient HCV replication than an uncloned population of MT-2 cells. Treatment of HCV-infected MT-2C cells with the antisense oligonucleotide (10 microM) had a dramatic inhibitory effect on viral replication. This result suggests that the antisense oligonucleotide complementary to the sequence close to the initiation codon of the core region might be useful as an antiviral agent against HCV replication.

Antiviral Agents↗
PubMed1995

Sequence specificity on the growth suppression and induction of apoptosis of chronic myeloid leukemia cells by BCR-ABL anti-sense oligodeoxynucleoside phosphorothioates.

Sequence specificity of inhibitory effects of various BCR-ABL anti-sense oligodeoxynucleoside phosphorothioates (AS PS-ODN) on the proliferation of the chronic myeloid-leukemia cell line BV173 was examined. We confirmed that 26, 18, and 16mer B2A2 AS PS-ODN had strong inhibitory effects on the proliferation of BV173 cells with B2A2 mRNA expression, and that B3A2 AS PS-ODN were equally inhibitory when cultures were initiated at lower cell concentrations. However, at higher cell concentrations, the inhibitory effects by B3A2 AS PS-ODN were reduced and B2A2 AS PS-ODNs could suppress the proliferation of BV173 cells with much more relative sequence specificity. The 26mer B2A2 AS PS-ODN induced apoptosis of BV173 cells following reduction of BCR-ABL mRNA expression and p210 protein synthesis. Various sense (S), reverse order, and random sequences had no inhibitory effects except 16mer B2A2 S and B3A2 S that revealed significant suppressive effects. Furthermore, 26mer B3A2 AS also reduced B2A2 mRNA expression and p210 protein synthesis, while 16mer S sequences did not. These results suggest that B2A2 AS may be cross-reactive with B3A2 AS on the growth suppression of CML cells under certain culture conditions, possibly due to their partial hybridization to the ABL portion of the target mRNA, although other non-sequence-specific mechanisms are also possible.

Base Sequence↗
PubMed1995

Inhibition of proliferation by L-myc antisense DNA for the translational initiation site in human small cell lung cancer.

We evaluated the antiproliferative effect of L-myc antisense DNA in NCI-H209, a human small cell lung cancer (SCLC) cell line overexpressing the L-myc gene. The synthetic DNA used in the present study was oligodeoxynucleoside phosphorothioate, which showed rapid incorporation into NCI-H209 cells and localized mainly in the cell nucleus and weakly in the cytoplasm. The exposure of this cell line to L-myc antisense DNA covering the translational initiation site of L-myc proteins inhibited the cell proliferation in a dose-dependent sequence-specific manner. Furthermore, the growth inhibition by this antisense DNA was correlated with the level of L-myc expression in three SCLC cell lines, NCI-H209, NCI-H510, and NCI-H82. In Western blot analysis, expression of the L-myc proteins was down-regulated in the antisense-treated cells compared with control-treated cells in NCI-H209. Together with unique characteristics of the L-myc gene, including: (a) a frequently amplified and overexpressed state in SCLC; and (b) very restricted and low-level expression in human adult tissues, the present data indicate that L-myc is a good candidate for the target gene for antisense DNA therapy based on molecular biological diagnosis in SCLC.

Base Sequence↗
PubMed1995

Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells.

This study was designed using c-myc antisense oligodeoxynucleoside phosphorothioate (AS PS-ODN) to evaluate how alterations of c-myc expression in HL-60 human myeloid leukemia cells could influence the induction of apoptosis. Unexpectedly both the continuous down-regulation of c-myc expression caused by exposure to c-myc AS PS-ODN and up-regulation after its withdrawal influenced apoptosis. We found that continuous suppression of c-myc expression by 10 microM c-myc AS PS-ODN could decrease the proliferation of HL-60 cells to approximately 60% of the control growth after 3 days of suspension culture, and when assessed morphologically the percentage of cells undergoing apoptosis was 3.5%. Evidence either of cell cycle arrest or cell cycle prolongation was not detected. It is likely that apoptosis induced by the sustained down-regulation of c-myc expression with AS PS-ODN treatment was solely sufficient to explain the inhibition of cell proliferation. Up-regulation of c-myc expression was observed within 1 h after c-myc AS PS-ODN withdrawal. This up-regulation further enhanced induction of apoptosis and involved up to 32% of the cells. These results suggest that while the continuous suppression of c-myc expression caused a constant effect on the induction of apoptosis, its abrupt up-regulation could rapidly drive a considerable number of HL-60 cells into the apoptotic pathway.

Apoptosis↗
PubMed1995

Missense mutation of rhodopsin gene codon 15 found in Japanese autosomal dominant retinitis pigmentosa.

Heterozygous missense mutation in codon 15 of the rhodopsin gene was detected in a patient with autosomal dominant retinitis pigmentosa (ADRP), where a transition of adenine to guanine at the second nucleotide in codon 15 (AAT-->AGT), corresponding to a substitution of serine residue for asparagine residue (Asn-15-Ser) was detected. None of the remaining unrelated 42 ADRP, 24 autosomal recessive RP (ARRP) and 34 normal individuals had this alteration. Her funduscopic findings were sectorial in type similar to that of the patients with the same mutation found in an Australian pedigree (Sullivan et al., 1993). This study shows phenotypic similarities in patients with the same mutation of a different ancestry.

Amino Acid Sequence↗
PubMed1995

Cloning and sequence of the SCS2 gene, which can suppress the defect of INO1 expression in an inositol auxotrophic mutant of Saccharomyces cerevisiae.

Saccharomyces cerevisiae ire15 mutant has a defect in the expression of INO1, showing the inositol auxotrophic phenotype [Nikawa, J. (1994) Gene 149, 367-372]. We have isolated five yeast genes which suppress the ire15 mutation in multiple copies by genetic complementation. Among them, one gene, designated as SCS2, also suppressed the choline-sensitive dominant mutation, CSE1 [Hosaka, K. et al. (1992) J. Biochem. 111, 352-358]. The CSE1 mutation is not allelic to ire15. Sequencing analysis revealed that the SCS2 gene encodes 244 amino acid residues with a calculated molecular mass of 26,866. INO2/SCS1, which is another suppressor gene for CSE1 and is known to be a positive factor for INO1 expression, also suppressed the growth defect of the ire15 mutant. These results clearly indicate that the ire15 and CSE1 mutations genetically interact and the SCS2 and INO2/SCS1 genes are involved in the regulation of INO1 expression.

Amino Acid Sequence↗
PubMed1995

Low dose famotidine in the prevention of sleep disturbance caused by heartburn after an evening meal.

AIM: To determine whether, in a susceptible population, dosing with 10 mg famotidine 1 h before an evening meal could decrease the interference with sleep caused by heartburn. METHODS: Patients with a history of frequent heartburn (n = 309) were randomized to receive 10 mg famotidine or placebo 1 h before an evening meal likely to induce symptoms. Patients assessed the efficacy of the treatment in preventing heartburn after the meal, at bedtime and during the night. The number of awakenings due to heartburn and the consumption of antacid tablets taken to alleviate symptoms were also recorded. RESULTS: Treatment groups were well matched and data from 302 patients were available for analysis. Compared to placebo, famotidine treated patients had: less heartburn after the meal (P < 0.0001 mean global scores), less interference with getting to sleep (P = 0.0156 mean global scores), fewer awakenings (P = 0.0001 difference in mean number) and better control of heartburn during the night (P < 0.0001 mean global scores). They were also almost three times less likely to need antacid treatment than the placebo group during the night (relative odds for no antacid 2.78 (95% CI: 1.29-5.96). Only four patients in each group suffered adverse events. CONCLUSION: Taking a 10 mg dose of famotidine 1 h before an evening meal appears to be a successful and well tolerated strategy for preventing post-prandial heartburn and avoiding the associated interference with sleep.

Adult↗
PubMed1995

Effects of phosphoramidon on endothelin-1 and big endothelin-1 production in human aortic endothelial cells.

Using cultured human aortic endothelial cells, we examined the effects of phosphoramidon, an endothelin converting enzyme (ECE) inhibitor, on the release of endogenous endothelin-1 (ET-1) and big endothelin-1 (big ET-1), and on the generation of ET-1 from exogenously applied big ET-1. Phosphoramidon, at concentrations of 10(-6) to 2 x 10(-4) M, caused a biphasic alteration of the ET-1 release, i.e., at lower concentrations of the drug, there were slight but unexpected increases of the release, whereas higher concentrations led to a decrease which is due to the drug-induced inhibition of ECE. The former effect appears to be based on the inhibition of ET-1 degradation by neutral endopeptidase 24.11 (NEP), since kelatorphan, a specific NEP inhibitor, produced a similar increasing effect on ET-1 release. Phosphoramidon enhanced the big ET-1 release from the cells in a concentration-dependent manner. When high concentrations of phosphoramidon were added, there was a dramatic increase in the release of big ET-1, which cannot be explained only by the drug-induced inhibition of ECE. This increase in big ET-1 release appeared to be partly due to a transient stimulation of the expression of prepro ET-1 mRNA. The amount of ET-1 generated from exogenously applied big ET-1 was markedly decreased by phosphoramidon in a concentration-dependent manner. In a similar fashion, phosphoramidon markedly inhibited ECE activity of the membrane fraction of cultured cells. Thus, ET-1 generation from exogenously applied big ET-1 reflects the functional phosphoramidon-sensitive ECE activities in human aortic endothelial cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Analgesics↗
PubMed1995

Screening of tissue cultures and thalli of lichens and some of their active constituents for inhibition of tumor promoter-induced Epstein-Barr virus activation.

Inhibition of tumor promoter-induced Epstein-Barr virus (EBV) activation was screened using tissue culture and thallus extracts of lichens. Usnea longissima ACH. thallus and Cetraria ornata MULL. ARG. tissue culture showed strong inhibitory activity. We identified (+)-usnic acid (1), barbatic acid (2), diffractaic acid (3), 4-O-demethylbarbatic acid (4), and evernic acid (5) as inhibitors of EBV activation from the U. longissima thallus. Of these compounds, (+)-usnic acid exhibited the highest inhibitory activity (IC50 = 1.0 microM).

Anticarcinogenic Agents↗